Search Results

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Ajinomoto Co., Inc. launched a new version of its StemFit™ iPSC expansion medium.

March 26, 2024

·

3 min read

Deals

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.

November 13, 2023

·

4 min read

Biotech Beach

Ajinomoto Bio-Pharma Services Garners Six ‘CDMO Leadership Awards,’ Further Establishing Its Industry Excellence

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups.

March 12, 2024

·

2 min read

Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios

Ajinomoto Co., Inc., the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on “AminoScience,” has expanded its corporate venture capital arm with new U.S. headquarters to grow its investments in U.S. and global companies.

February 13, 2024

·

2 min read

Business

Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility

Ajinomoto Bio-Pharma Services today announced leadership changes at the company’s site in San Diego, effective immediately.

May 18, 2023

·

3 min read

FDA

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

Ajinomoto Bio-Pharma Services is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company’s high potency vial line to manufacture a commercial product.

April 19, 2023

·

1 min read

Business

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs.

January 10, 2023

·

4 min read

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

Ajinomoto Bio-Pharma Services is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.

February 22, 2023

·

3 min read

Pictured: Businessmen shaking hands after closing a deal

Deals

Ajinomoto Targets Gene Therapy Space with $620M Forge Acquisition

The Japanese biotechnology and food company has bought into the gene therapy space with its $620 million acquisition of Ohio-based CDMO and clinical-stage biotech Forge Biologics.

November 14, 2023

·

2 min read

·

Tristan Manalac

Business

Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance

Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations.

January 25, 2022

·

2 min read